MML Investors Services LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 7.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,914 shares of the company’s stock after selling 2,226 shares during the period. MML Investors Services LLC’s holdings in Eli Lilly and were worth $2,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Acrospire Investment Management LLC raised its stake in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. Point72 Asia Hong Kong Ltd raised its stake in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new position in Eli Lilly and in the 2nd quarter worth $148,000. Cornerstone Advisors Inc. raised its stake in Eli Lilly and by 18.4% in the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after acquiring an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC raised its stake in Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after acquiring an additional 176 shares during the last quarter. Institutional investors own 75.48% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 770,000 shares of company stock worth $64,669,850. 0.20% of the stock is currently owned by insiders.

A number of brokerages recently issued reports on LLY. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a research note on Wednesday, November 1st. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Berenberg Bank reiterated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Leerink Swann lifted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $89.76.

ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) Shares Sold by MML Investors Services LLC” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-shares-sold-by-mml-investors-services-llc/1699463.html.

Shares of Eli Lilly and Company (NYSE:LLY) opened at $83.29 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a twelve month low of $64.18 and a twelve month high of $89.09. The stock has a market capitalization of $91,710.21, a PE ratio of 20.36, a P/E/G ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the firm posted $0.88 EPS. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. equities research analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.